Custom synthesised and pre-designed probes and primers

Pick and choose which COVID-19 signatures work best for your lab with individual RUO probes and primers using sequences as designated by Charité and US CDC protocols:

• 

  Influenza SARS-CoV-2 Multiplex ValuPanel Reagents

• 

  2019-nCoV ValuPanel Reagents

• 

  Charité 2019-nCoV BBQ-650 ValuPanel Reagents

• 

  Charité 2019-nCoV BHQ ValuPanel Reagents

• 

  Yale 2019-nCoV SalivaDirect ValuPanel Reagents

Custom, bulk oligos that can scale with demand

• 

  See all DNA probe formats

Nucleic Acid Chemistry reagents for in-house synthesis

We are the inventor and source manufacturer of BHQ™ and BBQ™ dyes, not to mention CAL Fluor™ and Quasar™ products, and support oligonucleotide synthesis with decades of combined expertise and experience from our Prime Synthesis, BioAutomation, LINK and Berry & Associates brands.

• 

  Nucleic acid chemistry products and high-throughput instruments

LGC Clinical Diagnostics offer a complete Quality Solution for COVID-19 diagnostic assay validation

AccuPlex™ technology mimics wild-type pathogenic viruses, but is safe, non-infectious, and replication deficient. These materials serve as true, full-process quality solutions that challenge the entire diagnostic workflow, making them the preferred alternative to infectious materials.

Together, the AccuPlex SARS-CoV-2 Verification Panel and AccuPlex SARS-CoV-2 Reference Material Kit offer an ideal solution for clinical laboratories looking for a safe, effective tool to verify and monitor SARS-CoV-2 molecular assay performance. Products contain positive materials directed against the published CDC and WHO consensus sequences and the S gene. Negative materials targeting the human RNase P gene are also included.

“We just went ‘live’ with the SARS-CoV-2 assay…I’ve never brought in and validated an assay in 7 days. The LGC Clinical Diagnostics (formally LGC SeraCare) reference materials works perfectly. I needed something other than the assay’s positive control to create a positive assay result before I felt comfortable releasing the assay for patient testing, and your product did the trick.”

Medical Director, Clinical Chemistry Laboratory prominent Boston Academic Medical Hospital

For testing

Confidently meet surging demand with a large-scale, end-to-end testing solution.

As the need for SARS-CoV-2 testing continues for both diagnostic and screening applications, many organisations are looking to create or shift testing capacity. An unpredictable market makes implementing a testing strategy challenging, calling for automation platforms that are able to adapt to fluctuating needs.

Biosearch Technologies offers fully automated PCR testing technology that is redefining high-throughput for SARS-CoV-2 detection to 35,000 tests per day on a single system. To further enable frequent, repeat testing, our ultra-high-throughput PCR testing system is capable of processing up to 150,000 tests per day on a single system.

For oligonucleotide synthesis

To support the demands of high-throughput oligo synthesis, we offer the MerMade™ 192E and MerMade™ 192X synthesizers. The 192E (and the robotic version 192R) is especially suited to less complex probes and primers and can synthesise 192 oligos in less than 3 hours, producing a very high-quality product with minimal reagent usage.